Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Detailed description
The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.
Primary outcome measures
- Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data [Time frame: 5 years]
Secondary outcome measures (3)
- Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases [Time frame: 5 years]
- Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions [Time frame: 5 years]
- Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
- All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
- Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
- Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
- Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
- Participating patients must agree to share their anonymized clinical and genomic data
Exclusion criteria
None.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Canada · 3 centers
- Kingston Health Sciences Centre — Kingston
- Ottawa Health Research Institute — Ottawa
- Princess Margaret Cancer Centre — Toronto
Identifiers
NCT: NCT05403177 · MOHCCN-O